I don't see TONE being that expensive a trial to run. A dermbration treatment averages between $150-300 in US. Vitiligo may be a bit more expansive than normal, so $5k per patient on the extremely conservative side. 100 patients, 100 kits at cost, $350k + $500k for treatment and follow up. Throw in $2M for data and documentation work. Spread out over 6 quarters you are looking at $500k per quarter. Pretty cheap clinical trial. Which should get them what they really need, vitiligo coverage by private insurers.
Ann: AVITA Medical Q3 Revenue & Secures $90M Non-Dilutive Debt, page-119
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.42 |
Change
0.010(0.41%) |
Mkt cap ! $160.4M | |||
| Open | High | Low | Value | Volume |
| $2.42 | $2.45 | $2.41 | $562.3K | 231.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 82002 | $2.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.43 | 16 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVH (ASX) Chart |